132 related articles for article (PubMed ID: 8724401)
1. Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis.
Cormican MG; Erwin ME; Marshall SA; Jones RN
Diagn Microbiol Infect Dis; 1996 Mar; 24(3):155-60. PubMed ID: 8724401
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Kitzis MD; Goldstein FW; Miegi M; Acar JF
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
[TBL] [Abstract][Full Text] [Related]
3. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Biedenbach DJ; Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
[TBL] [Abstract][Full Text] [Related]
4. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
Jones RN; Biedenbach DJ; Erwin ME; Beach ML; Pfaller MA
J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
Thornsberry C; Ogilvie P; Kahn J; Mauriz Y
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):249-57. PubMed ID: 9458982
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
7. Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
Barry AL; Fuchs PC; Allen SD; Jorgensen JH; Tenover FC; Murray PR; Hardy DJ; Baker CN
J Clin Microbiol; 1993 Sep; 31(9):2375-80. PubMed ID: 8408559
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of fluoroquinolones against common respiratory pathogens.
Aydemir S; Tunger A; Cilli F
West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
[TBL] [Abstract][Full Text] [Related]
9. Haemophilus test medium versus Mueller-Hinton broth with lysed horse blood for antimicrobial susceptibility testing of four bacterial species.
Barry AL; Pfaller MA; Fuchs PC
Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):548-53. PubMed ID: 8404918
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
Mendes C; Kiffer CR; Blosser-Middleton RS; Jones ME; Karlowsky JA; Barth A; Rossi F; Andrade S; Sader HS; Thornsberry C; Sahm DF;
Clin Microbiol Infect; 2004 Jun; 10(6):521-6. PubMed ID: 15191379
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
Doern GV; Vautour R
Diagn Microbiol Infect Dis; 1992; 15(7):633-40. PubMed ID: 1424521
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
Casellas JM; Gilardoni M; Tome G; Goldberg M; Ivanovic S; Orduna M; Dolmann A; Ascoli M; Ariza H; Montero JM
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():37-42. PubMed ID: 10404336
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Johnson DM; Biedenbach DJ; Beach ML; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
[TBL] [Abstract][Full Text] [Related]
15. Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
Zerva L; Biedenbach DJ; Jones RN
J Clin Microbiol; 1996 Aug; 34(8):1970-4. PubMed ID: 8818892
[TBL] [Abstract][Full Text] [Related]
16. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Biedenbach DJ; Barrett MS; Croco MA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Flamm RK; Rhomberg PR; Huband MD; Farrell DJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):6381-5. PubMed ID: 27458220
[TBL] [Abstract][Full Text] [Related]
18. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
20. Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme.
Reynolds R; Shackcloth J; Felmingham D; MacGowan A;
J Antimicrob Chemother; 2003 Dec; 52(6):925-30. PubMed ID: 14585864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
